A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

Prior treatment

• Participant is taking nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen/paracetamol, low-potency opioids (tramadol, codeine, hydrocodone, alone or in combination with acetaminophen), unless they have been on stable doses for ≥ 1 week prior to Baseline Visit; and/or oral corticosteroids (equivalent to ≤ 10 mg/day of prednisone), or inhaled corticosteroids for stable medical conditions unless they have been on stable doses for ≥ 4 weeks prior to Baseline Visit.
• History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than rheumatoid arthritis.

• At any time prior to the Screening Visit, participant must have been treated for > or = 3 months with at least 1 biologic/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) therapy but continued to exhibit active RA, or had to discontinue due to intolerability or toxicity, irrespective of treatment duration. The maximum cap for prior use of b/ tsDMARD is 2.
• Participant must be on a stable dose of methotrexate (MTX)